

Singular Health Group Ltd: SHG

ASX Announcement

16th August 2023

Strategic Investment from Singular's Master Distributor in USA

Highlights

- CG1 Ventures LLC ("CG1 Ventures"), venture arm of Singular's recently appointed Master Distributor for the USA, CG1 Solutions LLC ("CG1"), to invest up to \$850,000.
- CG1 Ventures to invest at AUD\$0.055 per share, a 41% premium to the last closing price of \$0.039, and the same price as the Company's last capital raise.
- Promising opportunities from recent representation at the Defense Health Information Technology Symposium (DHITS) hosted by US Defence Health Agency in New Orleans.

Singular Health Group Limited (**ASX: SHG**, "**Singular Health**", or the "**Company**"), a medical technology company delivering personalised healthcare through technology, is pleased to announce that it has received a binding commitment to raise a minimum of A\$500,000 to a maximum of A\$850,000 through the issue of fully paid ordinary shares in the Company to CG1 Ventures as part of a strategic investment ("**Strategic Placement**") at a 41% premium to the last closing price of \$0.039 per share.

The Strategic Placement is being conducted on the same terms as the Tranche 1 placement in the recent Capital Raise, being \$0.055 per share and with one free attaching option (\$0.10, three-year expiry from date of issue) (**Option**) for every two placement shares issued. Under the minimum investment of \$500,000 this equates to 9,090,909 Shares and 4,545,454 Options, and under the maximum investment of \$850,000 it would be 15,454,545 Shares and 7,727,272 Options (the "**Placement Securities**"). The issue of the Placement Securities will be subject to shareholder approval at a shareholder general meeting to be convened as soon as possible.

CG1 Ventures is the venture arm of Charlie Golf One Solutions, LLC, a Service-Disabled Veteran-Owned Small Business Concern (SDVOSBC) information technology firm based in South Florida, which was recently appointed as Singular Health's Master Distributor in July 2023 (refer ASX Announcement: Appointment of Master Distributor in the United States, 6th July 2023).

Representation at DHITS 2023

Building upon the appointment of CG1 Solutions as a Master Distributor in early-July, and in partnership with Seventeen Consulting, Singular Health's Washington DC-based Public Sector Sales Partner, the Company attended the 2023 Defence Health Information Technology Symposium (DHITS) last week.

Singular's Chief Operating Officer, James Hill, and Global Partnerships Manager, Dr. Martina Mariano, were present at the event. This Participation afforded the Company direct interaction with military procurement decision-makers who displayed keen interest in idea of using the 3Dicom Mobile app to securely store service personnel's medical records within their personal devices.

Commenting on the Strategic Investment, Singular Health Group's Interim Managing Director and Chief Executive Officer, Denning Chong, said:

"We are very pleased to welcome CG1 Ventures' strategic investment in Singular Health as we plant the flag in Florida and continue to grow our footprint in the United States through our Master Distributor, CG1 Solutions, and their team of sales partners.

"Building on from our appointment of CG1 Solutions as our Master Distributor in the United States just last month, this investment is a strong sign of confidence in achieving commercial contracts in the near-term future.

"These funds not only provide for additional capital and runway as we pursue larger scale enterprise opportunities in the United States but demonstrate a much closer collaboration between Singular Health and CG1, and the strong interest in the 3Dicom software in the United States both commercially and corporately."

This announcement is authorised for release by the Board of Directors of the Company.

Ends

For further information contact

Investors	Corporate
James Hill +61 413 825 646 jhill@singular.health	Steven Wood Company Secretary + 61 8 9322 7600

About Singular Health:

Singular Health Group Limited (ASX: SHG) is a medical technology company utilising advanced technologies to develop patient-specific solutions.

Singular Health's 3Dicom software solutions empower patients and practitioners to better visualise, communicate, and understand medical imaging data. 3Dicom MD® is cleared for diagnostic use in the United States.

Singular 3DP, a wholly owned subsidiary of Singular Health, uses advanced manufacturing including 3D printing and post-processing to manufacture TGA-approved patient-specific medical devices. It also provides hardware solutions as an official reseller of the 3D Systems, Kings 3D, and DyeMansion brands in the Australian and New Zealand markets.

To learn more, visit: <https://www.singular.health> and <https://investors.singular.health/>